StockWatch
·

FORTIS HEALTHCARE LTD. Q2 FY27 Results

FORTISQ2 FY27 Results
Filing
Result:Steady· Market: Crashed#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue2.7K7.5%17.3%
Total Income2.7K7.1%16.5%
Expenditure2.3K4.9%18.5%
PBT426.2518.8%1.1%
Net Profit320.4717.5%2.5%
OPM22.90%1.42pp1.97pp
NPM11.69%1.03pp2.28pp
EPS4.1417.3%2.8%
View full financials

Revenue grew a healthy 17.3% YoY but core profitability metric (EBITDA/OPM 24.9%→22.9%, NPM 14.0%→11.7%) compressed, leaving adjusted PAT down 2.5% YoY — in-line top line masked by margin erosion, not a standout quarter.

FORTIS HEALTHCARE · Q2 FY27 · THE VERDICT

Revenue Up 17%, Profit Down 2% — The Execution Test Begins

Fortis posted strong 17.3% revenue growth but saw PAT decline 2.5% YoY. The gap reveals the real tension: can management convert expansion scale into profit growth when ESOP costs, new-unit ramp-up, and drug price controls are eating the margin gains?

10 Nov 2026 · 6 min read

On paper, Fortis delivered a confident quarter: revenue jumped to ₹2,735 Cr, hospitals grew 18.6%, occupancy ticked higher to 72%, and EBITDA margin expanded 30 basis points to 24.2%. But there is a disconnect that defines the read: profit fell 2.5% YoY despite revenue climbing 17.3%. That gap is not accounting noise — it is execution stress, and it matters.

Reported PAT

₹320.5 Cr

-2.5% YoY

EBITDA

₹663 Cr

+19.2% YoY at 24.2%

Revenue

₹2,735 Cr

+17.3% YoY

NPM

11.7%

vs prior ~15%, flow-through stalled

Where the margin went

EBITDA grew 19.2% but PAT declined. Three headwinds explain the disconnect. First, ESOP. Management flagged ₹140 Cr annual ESOP expense in FY27, which masks underlying operational margins. Second, new-unit ramp-up drag. Manesar and People Tree remain below target occupancy. Bangalore's Suguna acquisition sits at just 63% occupancy. FMRI, the flagship ₹200 Cr Delhi facility, has not yet been operationalized for profitability — critical oncology unit delayed to Q4 FY27. Third, near-term cost inflation and drug price controls. 137 oncology drugs are now under price caps; impact is unquantified but material. Management admitted it is 'very difficult' to assess the exact margin hit, but one-third of oncology revenue (~₹60–70 Cr) is exposed.

It is very difficult, this circular is very recent. We are still figuring out how it will be impacting the margins and all.

Management's claims: the report card

What management said vs. what the numbers show
Claim on the callDelivered metricVerdict
Hospital revenue 18.6% YoY to ₹2,340 CrQ2 achieved ₹2,340 Cr (+18.6%)Supported
Diagnostics 12.2% YoY to ₹448 Cr grossQ2 confirmed at 12.2%Supported
EBITDA margins improving to 24.2%₹663 Cr at 24.2% (+30 bps YoY)Supported
PAT growth 4% to ₹317 Cr pre-exceptionalDelivered ₹320.5 Cr but -2.5% YoYOverstated
500+ beds expected FY27; 2,000 by FY30Suguna 110 live + brownfield ~200/year in pipelineSupported (concrete pathway)

What changed on this call

Bed expansion accelerated. Suguna acquisition (1,000 beds, expandable to 1,150) brought forward; greenfield Delhi hospital (₹400 Cr) with 3–4 year timeline now on the roadmap. Total committed CAPEX ₹3,500 Cr over 3–3.5 years, up from prior ₹400-bed guidance. Margin guidance caveated. Previously confident '25% EBITDA by FY28' now heavily qualified. Management explicitly refrained from FY28 margin guidance due to drug price control uncertainties and new-unit ramp-up timing. Signal: near-term caution. Diagnostics guidance maintained. Held 12–13% FY27 growth target; Q2 achieved 12.2%. Wellness now 15% of diagnostics revenue (up from 13%), but overall volume growth muted at 5.8% YoY — offset by pricing gains.

The bull-bear ledger

  • Hospital segment +18.6% driven by occupancy gains (72%) and ARPP growth (+6.8%)

  • Multi-year bed expansion roadmap concrete: 500+ FY27, 2,000 by FY30 with committed ₹3,500 Cr CAPEX

  • EBITDA margin expanding (+30 bps YoY) despite new-unit drag; 15 hospitals at >20% margin (84% of revenue)

  • Profit declined 2.5% YoY despite 17.3% revenue growth — indicates execution friction

  • ESOP ₹140 Cr annual burden masks underlying margins; flow-through collapsed

  • New-unit integration below target: Bangalore 63% occupancy, FMRI OP pending, Manesar/People Tree in ramp-up

  • Drug price controls on 137 oncology drugs (one-third of oncology revenue exposed) — impact unquantified

Risks, ranked by how much they should concern a holder

Key risks and why they matter

Drug price controls on oncology (137 drugs)

HIGH

Magnitude still unquantified. One-third of oncology revenue (~₹60–70 Cr) exposed. Management cannot model impact confidently. Could compress margins 100–150 bps if hit wholesale.

New-unit ramp-up execution delays

HIGH

FMRI flagship ₹200 Cr project not yet profit-accretive; oncology unit delayed to Q4 FY27. Bangalore occupancy 63%. Raised execution risk on integration and occupancy ramp timelines.

Margin guidance deferral (no FY28 guidance)

MEDIUM

Management explicitly withheld FY28 margin guidance due to uncertainties. Signals caution on near-term margin recovery. Prior confidence on '25% by FY28' now qualified.

ESOP cost burden (~₹140 Cr FY27)

MEDIUM

Masks underlying operational margin. Until ESOP winds down or is capitalized differently, reported PAT will remain pressured relative to EBITDA growth.

Leverage for ₹3,500 Cr CAPEX expansion

MEDIUM

Net debt ₹2,188 Cr (0.87x EBITDA). CAPEX commitment requires debt/internal accrual. If revenue growth or margins miss, leverage could spike.

Forensic audit and regulatory overhang

LOW

Court-ordered 6-month audit; IHH stake increase possible but procedural. Minimal near-term constraint but overhang on strategic moves.

How the street is positioned

The market has been harsh. Stock at ₹774.55, down 29.86% from its all-time high, trading below all key moving averages (SMA20 ₹756, SMA50 ₹817, SMA200 ₹892). RSI at 48.6 (neutral) suggests oversold conditions are fading. Institutional flows reveal the tension: FII has trimmed 77 basis points (from 25.97% to 25.20% Q-o-Q), while DII has accumulated 88 basis points (31.35% to 32.23%). Promoter holding flat at 31.17%. The story: foreign funds are retreating on execution/margin concerns; domestic institutions are accumulating on valuation. The drawdown from the all-time high is steep — 30% is a significant repricing, and it reflects the market's own verdict: execution risk is real, and margin recovery is not yet credible.

What to watch next (Q3 FY27–Q4 FY27)
  • 1 · FMRI operationalization and oncology profitability

    Flagship Delhi facility must commission radiation oncology unit by Q4 FY27. Profit contribution will signal execution capability on flagship ₹200 Cr project and validate multi-year bed expansion roadmap.

  • 2 · Drug price controls impact quantification

    Management must publish concrete margin impact (percentage points) of oncology price controls. Until then, FY28 guidance will remain uncertain. Q3 or Q4 clarity is critical to investor confidence.

  • 3 · Bangalore and Manesar occupancy ramp-up

    Bangalore at 63% is a red flag for integration speed. Manesar still in ramp-up. Next 2 quarters will show whether occupancy converges to network average (72%). Misses extend margin recovery timeline.

Fortis delivered a steady quarter on the headline: revenue growth is robust, EBITDA margin is expanding. But the profit miss — a 2.5% decline despite 17% revenue growth — reveals this is an execution test, not a growth story. The company is betting that new units (FMRI, Manesar, Bangalore) will mature, drug price controls will be quantified and managed, and ESOP costs will tail off. Until then, profit growth remains constrained. The stock's 30% drawdown from the all-time high has repriced it for caution; DII is accumulating, FII is retreating. The next two quarters will resolve whether this is a correction or a re-rating. Watch FMRI operationalization, drug price impact, and occupancy ramp. The number to track: adjusted PAT growth (stripping ESOP) — that will tell you whether management is executing or just expanding without profit.

Informational and educational content only. Not investment advice.